These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

455 related items for PubMed ID: 18375542

  • 1. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis.
    de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ.
    Ann Rheum Dis; 2009 Apr; 68(4):531-5. PubMed ID: 18375542
    [Abstract] [Full Text] [Related]

  • 2. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.
    de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, Hazenberg BP, Wolbink GJ.
    Arthritis Rheum; 2009 Nov 15; 61(11):1484-90. PubMed ID: 19877087
    [Abstract] [Full Text] [Related]

  • 3. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data.
    Baraliakos X, Brandt J, Listing J, Haibel H, Sörensen H, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2005 Dec 15; 53(6):856-63. PubMed ID: 16342093
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
    Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M, Sieper J, Braun J.
    Rheumatology (Oxford); 2005 Mar 15; 44(3):342-8. PubMed ID: 15561737
    [Abstract] [Full Text] [Related]

  • 5. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
    Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmartí R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S.
    Ann Rheum Dis; 2004 Dec 15; 63(12):1594-600. PubMed ID: 15345498
    [Abstract] [Full Text] [Related]

  • 6. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
    Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L, Rudwaleit M, Sieper J, Braun J.
    Arthritis Rheum; 2003 Jun 15; 48(6):1667-75. PubMed ID: 12794835
    [Abstract] [Full Text] [Related]

  • 7. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
    Woo JH, Lee HJ, Sung IH, Kim TH.
    J Rheumatol; 2007 Aug 15; 34(8):1753-9. PubMed ID: 17610317
    [Abstract] [Full Text] [Related]

  • 8. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
    van der Heijde D, Da Silva JC, Dougados M, Geher P, van der Horst-Bruinsma I, Juanola X, Olivieri I, Raeman F, Settas L, Sieper J, Szechinski J, Walker D, Boussuge MP, Wajdula JS, Paolozzi L, Fatenejad S, Etanercept Study 314 Investigators.
    Ann Rheum Dis; 2006 Dec 15; 65(12):1572-7. PubMed ID: 16968715
    [Abstract] [Full Text] [Related]

  • 9. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep 15; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

  • 10. [Clinical study of etanercept for treating ankylosing spondylitis].
    Liang LQ, Zhan ZP, Ye YJ, Fu D, Xu HS, Yang XY.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug 15; 28(8):1349-51. PubMed ID: 18753057
    [Abstract] [Full Text] [Related]

  • 11. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
    Yang CH, Huang F, Deng XH, Zhang JL, Zhang LY, Guo JH, Liang DF, Wang LS, Zhang YM.
    Zhonghua Yi Xue Za Zhi; 2006 Sep 19; 86(35):2451-4. PubMed ID: 17156669
    [Abstract] [Full Text] [Related]

  • 12. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
    Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.
    Ann Rheum Dis; 2006 Feb 19; 65(2):201-8. PubMed ID: 16014677
    [Abstract] [Full Text] [Related]

  • 13. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
    Braun J, McHugh N, Singh A, Wajdula JS, Sato R.
    Rheumatology (Oxford); 2007 Jun 19; 46(6):999-1004. PubMed ID: 17389658
    [Abstract] [Full Text] [Related]

  • 14. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, Inman RD, Kivitz A, Zhou L, Solinger A, Tsuji W.
    Ann Rheum Dis; 2005 Nov 19; 64(11):1557-62. PubMed ID: 15843448
    [Abstract] [Full Text] [Related]

  • 15. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
    Davis JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W, Enbrel Ankylosing Spondylitis Study Group.
    Arthritis Rheum; 2003 Nov 19; 48(11):3230-6. PubMed ID: 14613288
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
    Davis JC, van der Heijde DM, Braun J, Dougados M, Clegg DO, Kivitz AJ, Fleischmann RM, Inman RD, Ni L, Lin SL, Tsuji WH.
    Ann Rheum Dis; 2008 Mar 19; 67(3):346-52. PubMed ID: 17967833
    [Abstract] [Full Text] [Related]

  • 17. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 19; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 18. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis.
    Arends S, van der Veer E, Groen H, Houtman PM, Jansen TL, Leijsma MK, Bijzet J, Limburg PC, Kallenberg CG, Spoorenberg A, Brouwer E.
    J Rheumatol; 2011 Aug 19; 38(8):1644-50. PubMed ID: 21632677
    [Abstract] [Full Text] [Related]

  • 19. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis.
    Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Mar 19; 46(3):439-41. PubMed ID: 17255137
    [Abstract] [Full Text] [Related]

  • 20. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
    Gorman JD, Sack KE, Davis JC.
    N Engl J Med; 2002 May 02; 346(18):1349-56. PubMed ID: 11986408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.